Willingness to pay for one quality-adjusted life year in Iran.
Cost-effectiveness threshold value
Quality-adjusted life year
WHO threshold value
Willingness to pay
Journal
Cost effectiveness and resource allocation : C/E
ISSN: 1478-7547
Titre abrégé: Cost Eff Resour Alloc
Pays: England
ID NLM: 101170476
Informations de publication
Date de publication:
2019
2019
Historique:
received:
19
04
2018
accepted:
12
02
2019
entrez:
15
3
2019
pubmed:
15
3
2019
medline:
15
3
2019
Statut:
epublish
Résumé
Recent years have witnessed a strong tendency to apply economic evidence as a guide for making health resource allocation decisions, especially those related to reimbursement policies. One such measure is the use of the cost-effectiveness threshold as a benchmark. This study explored the threshold for use in the health system of Iran by determining society's preferences. A cross-sectional household survey based on the contingent valuation method was administered to a representative general population of 1002 in Tehran, Iran from April to June 2015. The survey was intended to estimate the respondents' willingness-to-pay (WTP) preferences for one quality-adjusted life year (QALY) gained. The valuation scenarios featured 12 vignettes on mild to severe diseases that can change people's quality of life. The mean of WTP for QALY was estimated using different health instruments, and the determinants of such willingness were analyzed using the Heckman selection model. WTP for QALY varied depending on the severity of a disease and the instrument used to determine health preferences. Mean low health state value were associated with high valuation. The best estimated WTP values ranged from US$1032 to US$2666 and 0.22-0.56 of Iran's local gross domestic product (GDP) per capita in 2014. Except for educational level, significant variables differed across different disease scenarios. Generally, a high health state valuation for target diseases, high income, high educational level, and being married were associated with high WTP for QALY. From the general public's perspective, the monetary value of QALY for mild to severe diseases with no risk of death was less than one GDP per capita. Therefore, the obtained valuation range is recommended as reference only for the adoption of interventions designed to improve quality of life. Future studies should estimate the threshold of interventions for life-threatening diseases or formulate transparent policies in such contexts.
Sections du résumé
BACKGROUND
BACKGROUND
Recent years have witnessed a strong tendency to apply economic evidence as a guide for making health resource allocation decisions, especially those related to reimbursement policies. One such measure is the use of the cost-effectiveness threshold as a benchmark. This study explored the threshold for use in the health system of Iran by determining society's preferences.
METHODS
METHODS
A cross-sectional household survey based on the contingent valuation method was administered to a representative general population of 1002 in Tehran, Iran from April to June 2015. The survey was intended to estimate the respondents' willingness-to-pay (WTP) preferences for one quality-adjusted life year (QALY) gained. The valuation scenarios featured 12 vignettes on mild to severe diseases that can change people's quality of life. The mean of WTP for QALY was estimated using different health instruments, and the determinants of such willingness were analyzed using the Heckman selection model.
RESULTS
RESULTS
WTP for QALY varied depending on the severity of a disease and the instrument used to determine health preferences. Mean low health state value were associated with high valuation. The best estimated WTP values ranged from US$1032 to US$2666 and 0.22-0.56 of Iran's local gross domestic product (GDP) per capita in 2014. Except for educational level, significant variables differed across different disease scenarios. Generally, a high health state valuation for target diseases, high income, high educational level, and being married were associated with high WTP for QALY.
CONCLUSION
CONCLUSIONS
From the general public's perspective, the monetary value of QALY for mild to severe diseases with no risk of death was less than one GDP per capita. Therefore, the obtained valuation range is recommended as reference only for the adoption of interventions designed to improve quality of life. Future studies should estimate the threshold of interventions for life-threatening diseases or formulate transparent policies in such contexts.
Identifiants
pubmed: 30867654
doi: 10.1186/s12962-019-0172-9
pii: 172
pmc: PMC6396529
doi:
Types de publication
Journal Article
Langues
eng
Pagination
4Références
Health Policy. 1999 May;47(2):97-123
pubmed: 10538292
Health Econ. 2003 Aug;12(8):609-28
pubmed: 12898660
Appl Health Econ Health Policy. 2002;1(2):89-95
pubmed: 14619255
J Health Econ. 2004 Mar;23(2):237-58
pubmed: 15019754
Value Health. 2004 Sep-Oct;7(5):518-28
pubmed: 15367247
BMJ. 2004 Oct 23;329(7472):972-5
pubmed: 15499118
Bull World Health Organ. 2007 Aug;85(8):607-14
pubmed: 17768519
Popul Health Metr. 2009 Jun 15;7:9
pubmed: 19527516
Expert Rev Pharmacoecon Outcomes Res. 2004 Jun;4(3):247-50
pubmed: 19807306
Cost Eff Resour Alloc. 2012 Jul 18;10(1):9
pubmed: 22808944
Soc Sci Med. 2013 Sep;92:92-104
pubmed: 23849283
Cost Eff Resour Alloc. 2014 Jul 11;12:15
pubmed: 25050084
Health Econ. 2015 Oct;24(10):1289-1301
pubmed: 25070495
Health Econ. 2015 Mar;24(3):280-93
pubmed: 25625510
Med J Islam Repub Iran. 2014 Dec 29;28:157
pubmed: 25695015
PLoS One. 2015 Apr 09;10(4):e0122760
pubmed: 25855971
Bull World Health Organ. 2015 Feb 1;93(2):118-24
pubmed: 25883405
Iran J Pharm Res. 2015 Fall;14(4):1305-16
pubmed: 26664402
Value Health. 2016 Jan;19(1):1-13
pubmed: 26797229
Health Policy Plan. 2017 Feb;32(1):141-145
pubmed: 27452949
Value Health. 2016 Dec;19(8):929-935
pubmed: 27987642
Bull World Health Organ. 2016 Dec 1;94(12):925-930
pubmed: 27994285
Int J Health Policy Manag. 2017 Feb 11;6(10):573-586
pubmed: 28949473
Iran J Pharm Res. 2017 Spring;16(2):823-833
pubmed: 28979338
Value Health. 2018 Jul;21(7):759-761
pubmed: 30005746